JTT 552

Drug Profile

JTT 552

Alternative Names: JTT-552

Latest Information Update: 23 Jul 2009

Price : $50

At a glance

  • Originator Japan Tobacco
  • Class Antigouts
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperuricaemia

Most Recent Events

  • 31 Mar 2009 Discontinued - Phase-II for Hyperuricaemia in Japan (PO)
  • 28 Nov 2006 Phase-I clinical trials in Hyperuricaemia in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top